Xencor (XNCR) Change in Receivables (2016 - 2026)
Xencor (XNCR) reported Change in Receivables of -$5.8 million for Q1 2026, up 75.22% year-over-year from -$3.3 million in Q1 2025, and up 75.22% quarter-over-quarter from -$23.4 million in Q1 2025.
Xencor (XNCR) Change in Receivables (2016 - 2026) Analysis & Trends
Xencor (XNCR) has 9 years of Change in Receivables data on file, last reported at -$5.8 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$5.8 million, up 75.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$77.5 million (down 72.63% YoY), and the FY2025 annual result was -$28.7 million, down 187.94% from the prior year.
- Change in Receivables improved to -$5.8 million in Q1 2026 per XNCR's latest filing, from -$23.4 million in the prior quarter.
- Over five years, Change in Receivables peaked at $26.8 million in Q1 2022 and troughed at -$38.9 million in Q2 2022.
- A 3-year average of -$10.1 million and a median of -$9.4 million in 2022 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 2378.74% in 2022 and fell as far as 301.24% in 2022.
- A 3-year view of Change in Receivables shows it stood at -$9.4 million in 2022, then tumbled by 148.78% to -$23.4 million in 2025, then soared by 75.22% to -$5.8 million in 2026.
- Business Quant data shows XNCR's Change in Receivables at -$5.8 million in Q1 2026, -$23.4 million in Q1 2025, and -$9.4 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -5.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.80 Mn |
| Mar 31, 2026 | -5.80 Mn |
| Mar 31, 2025 | -23.41 Mn |
| Mar 31, 2025 | -23.41 Mn |
| Sep 30, 2022 | -9.41 Mn |
| Sep 30, 2022 | -9.41 Mn |
| Jun 30, 2022 | -38.92 Mn |
| Jun 30, 2022 | -38.92 Mn |
| Mar 31, 2022 | 26.82 Mn |
| Mar 31, 2022 | 26.82 Mn |
| Dec 31, 2021 | 58.34 Mn |
| Dec 31, 2021 | 58.34 Mn |
| Sep 30, 2021 | 5.22 Mn |
| Sep 30, 2021 | 5.22 Mn |
| Jun 30, 2021 | -9.70 Mn |
| Jun 30, 2021 | -9.70 Mn |
| Mar 31, 2021 | 1.08 Mn |
| Mar 31, 2021 | 1.08 Mn |
| Dec 31, 2020 | 1.91 Mn |
| Dec 31, 2020 | 1.91 Mn |